title: Dosimetric evaluation of nanotargeted (188)Re-liposome with the MIRDOSE3 and OLINDA/EXM programs.
abstract: OBJECTIVE
  The OLINDA/EXM computer code was created as a replacement for the widely used MIRDOSE3 code for radiation dosimetry in nuclear medicine. A dosimetric analysis with these codes was performed to evaluate nanoliposomes as carriers of radionuclides ((188)Re-liposomes) in colon carcinoma-bearing mice.
  
  
  METHODS
  Pharmacokinetic data for (188)Re-N, N-bis (2-mercaptoethyl)-N',N'-diethylethylenediamine ((188)Re-BMEDA) and (188)Re-liposome were obtained for estimation of absorbed doses in normal organs. Radiation dose estimates for normal tissues were calculated using the MIRDOSE3 and OLINDA/EXM programs for a colon carcinoma solid tumor mouse model.
  
  
  RESULTS
  Mean absorbed doses derived from(188)Re-BMEDA and (188)Re-liposome in normal tissues were generally similar as calculated by MIRDOSE3 and OLINDA/EXM programs. One notable exception to this was red marrow, wherein MIRDOSE3 resulted in higher absorbed doses than OLINDA/EXM (1.53- and 1.60-fold for (188)Re-BMEDA and (188)Re-liposome, respectively).
  
  
  CONCLUSIONS
  MIRDOSE3 and OLINDA have very similar residence times and organ doses. Bone marrow doses were estimated by designating cortical bone rather than bone marrow as a source organ. The bone marrow doses calculated by MIRDOSE3 are higher than those by OLINDA. If the bone marrow is designated as a source organ, the doses estimated by MIRDOSE3 and OLINDA programs will be very similar.
authors.affiliation: Institute of Nuclear Energy Research, Taoyuan, Taiwan, ROC, chchang@iner.gov.tw.
authors.forename: Chih-Hsien
authors.initials: CH
authors.lastname: Chang
authors.forename: Ya-Jen
authors.initials: YJ
authors.lastname: Chang
authors.forename: Te-Wei
authors.initials: TW
authors.lastname: Lee
authors.forename: Gann
authors.initials: G
authors.lastname: Ting
authors.forename: Kwo-Ping
authors.initials: KP
authors.lastname: Chang
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy; D000818:Animals; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000532:radiotherapy; D005029:Ethylenediamines / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008081:Liposomes; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D049329:Nanostructures / Q000737:chemistry*; D009942:Organometallic Compounds / Q000008:administration & dosage* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011092:Polyethylene Glycols / Q000737:chemistry; D011874:Radiometry / Q000379:methods*; D012984:Software; D014018:Tissue Distribution
chemical_list: C521828:188Re-N,N-bis(2-mercaptoethyl)-N',N'-diethylethylenediamine; D005029:Ethylenediamines; D008081:Liposomes; D009942:Organometallic Compounds; D011092:Polyethylene Glycols